Cingulate (CINGW) Net Equity Issued and Repurchased (2023 - 2026)
Cingulate's (CINGW) quarterly Net Equity Issued and Repurchased came in at $5.1 million in Q2 2026, little changed on a YoY basis from $5.1 million in Q2 2025, and up 95.46% quarter-over-quarter from $2.6 million in Q4 2025.
Analysis
Cingulate (CINGW) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $5.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Equity Issued and Repurchased changed 0.0% year-over-year to $5.1 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (down 4.79% YoY), and the FY2025 full-year result was $10.2 million, down 60.76% from the prior year.
- Net Equity Issued and Repurchased rose to $5.1 million in Q2 2026 per CINGW's latest filing, from $2.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $9.9 million in Q1 2024 and bottomed at $254260.0 in Q2 2023.
- Historically, Net Equity Issued and Repurchased has averaged $3.2 million across 4 years, with a median of $2.3 million in 2025.
- The widest YoY moves for Net Equity Issued and Repurchased: up 1328.04% in 2025, down 81.13% in 2025.
- Over 4 years, Net Equity Issued and Repurchased stood at $819538.0 in 2023, then soared by 81.76% to $1.5 million in 2024, then soared by 73.76% to $2.6 million in 2025, then soared by 95.46% to $5.1 million in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $5.1 million, $2.6 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | - |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | - |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | 141.90 Mn |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | - |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 5.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.06 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | 354,259.00 |
| Mar 31, 2024 | 9.89 Mn |
| Dec 31, 2023 | 819,538.00 |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 254,260.00 |